These risks and uncertainties include, but are not limited to, the risks associated with the Clarus financial position, risk inherited and pharmaceutical development, and those factors described under the heading Risk Factors in the prospectus filed with the Securities and Exchange Commission, the SEC, under Rule 424(b)(3) on December 23, 2021, and those that are included in any of Clarus future filings with the SEC, including its Annual Report on 10-K for the year ended December 31, 2021 when filed.